According to Zacks, “Stealth BioTherapeutics Corp is a biopharmaceutical company. It is engaged in developing therapies to treat the mitochondrial dysfunction associated with genetic mitochondrial diseases and many common age-related diseases. The company’s product pipeline includes Elamipretide, SBT-20 and SBT-272 which are in clinical stage. Stealth BioTherapeutics Corp is based in Newton, Massachusetts. “
Separately, HC Wainwright set a $5.00 target price on shares of Eyepoint Pharmaceuticals and gave the stock a buy rating in a report on Friday, July 12th. Two equities research analysts have rated the stock with a hold rating and four have assigned a buy rating to the stock. The stock has a consensus rating of Buy and an average price target of $24.83.
Shares of MITO stock opened at $11.35 on Thursday. The firm has a market cap of $317.14 million and a P/E ratio of -8.05. The business’s 50 day moving average is $12.38. Stealth BioTherapeutics has a 52 week low of $10.70 and a 52 week high of $20.99.
Stealth BioTherapeutics (NASDAQ:MITO) last announced its earnings results on Wednesday, May 15th. The company reported ($0.12) EPS for the quarter, topping the consensus estimate of ($0.26) by $0.14. Analysts forecast that Stealth BioTherapeutics will post -0.18 earnings per share for the current year.
A hedge fund recently bought a new stake in Stealth BioTherapeutics stock. Dean Capital Investments Management LLC acquired a new stake in Stealth BioTherapeutics Corp (NASDAQ:MITO) during the first quarter, according to its most recent filing with the Securities & Exchange Commission. The firm acquired 50,420 shares of the company’s stock, valued at approximately $646,000. Dean Capital Investments Management LLC owned about 0.18% of Stealth BioTherapeutics as of its most recent SEC filing. Institutional investors and hedge funds own 1.09% of the company’s stock.
About Stealth BioTherapeutics
Stealth BioTherapeutics Corp, a clinical-stage biotechnology company, focuses on the discovery, development, and commercialization of therapies for diseases involving mitochondrial dysfunction. Its lead product candidate, Elamipretide, has the potential to treat rare genetic and common age-related mitochondrial diseases.
Further Reading: Capital Gains
For more information about research offerings from Zacks Investment Research, visit Zacks.com
Receive News & Ratings for Stealth BioTherapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Stealth BioTherapeutics and related companies with MarketBeat.com's FREE daily email newsletter.